Key facts
- This page summarizes Angela Thedinga's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Aug 2021, 21:25.
Angela Thedinga - 06 Aug 2021 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)
- Reporting relationship
- Chief Technology Officer
- Issuer ticker
- ADVM
- Reported as of
- 06 Aug 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2021, 21:25:16 UTC
- Next SEC filing
- 29 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- Angela Thedinga, by /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Angela Thedinga filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 10 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADVM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- Price
- $0.000000
- Shares after
- 150,000
- Date
- 06 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADVM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- Price
- $0.000000
- Shares after
- 120,000
- Date
- 06 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,000
- Exercise price
- $2.48
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Reflects the grants of performance stock units, pursuant to which: (a) 1/3 of the shares will vest upon dosing of the first subject in a Phase 2 clinical trial of ADVM-022 in wet age-related macular degeneration; (b) 1/3 of the shares will vest upon dosing of the first subject in a potentially registrational clinical trial of ADVM-022 or another product candidate owned or being developed by Adverum in wet age-related macular degeneration or another indication determined by the Compensation Committee to represent a significant unmet medical need; and (c) 1/3 of the shares will vest upon consummation of a strategic corporate transaction, not constituting a change in control, that is determined by the Compensation Committee to be transformative for Adverum, in each case contingent upon certification by the Compensation Committee of the achievement of such milestone and subject to the Reporting Person's continued service with the Issuer on each such vesting date. See Footnote 2.
Footnote F2
Non-exclusive examples of a strategic corporate transaction are (i) a collaboration with another company for the development and commercialization of a major asset, (ii) a substantial royalty-based or other structured financing, and (iii) the acquisition or in-license of a significant asset for development and commercialization.
Footnote F3
The options will vest in equal monthly installments over three years, such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.